Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer

Written By Mollie Rotmensch

Deng M. et al. Antibody Therapeutics. 2021; 4: 16-33.

Mollie Rotmensch
Previous

IO-202, a first-in-class LILRB4 antagonist antibody, activates dendritic cells and inhibits solid tumor growth in preclinical studies.

Next

A First-in-Human Phase 1 Study of the Anti-LILRB4 Antibody IO-202…